Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Actelion Q1 Profit Falls As Market Place Remains Challenging - Update

Swiss pharmaceutical firm Actelion Ltd. (ALIOF.PK) on Thursday reported lower profit for the first quarter, amid a decline in revenue and a strong Swiss franc. In addition, the company reaffirmed its 2012 flat core earnings forecast and upgraded product sales guidance to low single digit decrease.

GAAP net income fell to 45.06 million francs ($49.15 million) or 0.38 francs per share from 146.29 million francs or 1.20 francs per share in the prior year.

Core earnings, which are product sales minus cash operating expenses and other items, fell to 107.6 million francs from 127.9 million francs. Core earnings per share declined 31 percent to 0.66 francs.

Net revenue dropped to 417.47 million francs from 528.23 million francs a year earlier. Product sales slid 4 percent in local currencies to 415.8 million francs.

Thirty-seven percent of sales came from the U.S., 41 percent from Europe, 11 pecrent from Japan and another 11 percent from the rest of the world. In local currencies, pulmonary hypertension drug Tracleer's sales dropped 6 percent to 363.7 million francs.

Jean-Paul Clozel, CEO of Actelion, said the market place remains challenging as expected, due mainly to changes in the competitive landscape in the U.S. and strong pricing pressures in certain markets.

Actelion had previously expected product sales in local currencies in 2012 to decrease in the low-to mid-single digit range. In the first quarter, while overall pricing pressure remained high, the US pricing environment improved slightly.

The company's CFO Andrew Oakley said, "Unforeseen events excluded, Actelion can now provide an improved product sales forecast. The decrease in local currencies is now expected to be in the low-single digit range. Actelion remains on track to meet its previously issued guidance of flat 2012 core earnings."

Further, the company said it expects results for its second-generation endothelin receptor antagonist macitentan in morbidity/mortality PAH study in the next few weeks.

The stock closed lower by 3.01 percent at 32.21 francs on 531,269 shares.

Register
To receive FREE breaking news email alerts for Actelion Ltd., and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The terrorists, in this case, have won. In an unprecedented move that may have far-reaching cultural and political effects, Sony Pictures has scrapped the release of "The Interview." The plot of the film, a comedy starring Seth Rogen and James Franco, revolves around a fictional assassination... Here is a list of interesting stocks to watch on December 18. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed below and many more have been researched already, and... Oracle Corp. said Wednesday after the markets closed that its second quarter profit fell 2% from last year, hurt mainly by higher income tax expenses even as revenue increased 3%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.